Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-755-8 | CAS number: 71-48-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment.
Data source
Reference
- Reference Type:
- publication
- Title:
- Metabolic fate of inhaled Co aerosols in Beagle dogs
- Author:
- Kreyling WG, Ferron GA, Haider B
- Year:
- 1 986
- Bibliographic source:
- Health Physics 51(6): 773
Materials and methods
- Objective of study:
- distribution
- excretion
- Principles of method if other than guideline:
- Lung retention of Cobalt (57) in dogs after the inhalation of physically and chemically uniform particles of Co compounds was determined. Excreta and blood analysis were also performed to examine the clearance patterns. Organ analysis was performed to determine the fate of the long term burden of Co in the lungs and other organs.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Cobalt dinitrate
- EC Number:
- 233-402-1
- EC Name:
- Cobalt dinitrate
- Cas Number:
- 10141-05-6
- IUPAC Name:
- cobalt(2+) dinitrate
- Details on test material:
- - Physical state: solid particle
- Analytical purity: not reported
- Radiochemical purity (if radiolabelling): not reported
- Specific activity (if radiolabelling): 0.4 - 4 MBq
- Locations of the label (if radiolabelling): Co
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 57Co
Test animals
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: GSF breeding facility
- Age at study initiation: 10-16 mo
- Water (e.g. ad libitum): ad libitum
- Individual metabolism cages: yes, for a period 10 days post exposure
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TYPE OF INHALATION EXPOSURE: other: endotracheal tube
GENERATION OF TEST ATMOSPHERE / CHAMPER DESCRIPTION
- Exposure apparatus: according to Kreyling et al. (1976)
- Method of holding animals in test chamber: barbiturate anaesthesia, lateral position (right side)
- System of generating particulates/aerosols: modified May spinning top aerosol generator
- Composition of vehicle: phys. saline
- Method of particle size determination: low-angle forward-scattering spectrometer
- Treatment of exhaust air: removed
TEST ATMOSPHERE (if not tabulated)
- MMAD (Mass median aerodynamic diameter) / GSD (Geometric st. dev.): 1.5 µm / <1.2
- Geometric mean diameter: 1.1 µm - Duration and frequency of treatment / exposure:
- 30 to 60 min, single exposure
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1 to 1000 µg (not further specified)
- No. of animals per sex per dose / concentration:
- 2 males
- Control animals:
- no
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine (initially daily extraction using catheter, then four nights per week: 16 h urine), faeces, blood, blood cells, serum, lungs, bones, muscles, skin, stomach/intestine, liver, kidneys, spleen, trachea, tracheobronchial lymph nodes, trachea, upper 3-4 generations of bronchi
- Time and frequency of sampling: start immediately after inhalation, at time intervals increasing from daily to once every month and up to 600 days, for various periods, depending on the parameter investigated, for more than 4 years
Retention analysis of deposited Co and its spatial distribution in the lungs:
Measurement was performed using a γ camera. measurements began immediately after inhalation of the aerosols and was performed dorsally, from right and left side of each dog for 15 minutes in each position. Measurements were initially performed on a daily basis, then once every moth for up to a period of 4 years. Occasionally head, larynx or peritoneum were measured. The background radioactivity was subtracted from each picture, thoracic attenuation of retained Co activity was determined at each measurement. In order to correct lung retention for interference from Co retained in the thoracic walls and surrounding organs, thorax activity of the carcass of the dog without lungs was measured at the time of death.
Clearance analysis:
Clearance from bronchial tree and pulmonary region: determination began directly after the exposure. Quantitative collection of excreta during the first 10 days in metabolic cages. Daily extraction of urine by a urinary catheter before the retention measurements. During the next 6 months housing in separate kennels for quantitative faeces collection, during 4 nights/week urine samples of 16 hours were taken inside metabolic cages. After 6 months, excreta were taken for periods of 4 weeks at intervals up to 600 days after exposure. Daily faecal excretion of Co and urinary excretion rates of the first 10 days were determined. Later daily urinary excretion was estimated from measured concentration of Co and an assumed constant daily urinary volume. Blood samples were taken during the first 5-8 months after exposure, blood serum was separated and activity of both samples was determined.
Metabolic studies:
Transfer of Co from the circulatory system into the gastrointestinal (GI) tract and vice versa was studied by additional experiments. Transfer of endogenous Co from the blood was determined after intravenous injection into a leg vein and intramuscular injection into a rear leg muscle, absorption from the GI tract was measured after ingestion of the radiolabeled test compound by other dogs. Retention and excretion measurements were carried out up to 2 months. Liver retention was calculated from the measured abdominal retention by allowing for deposits in other tissues in the field of view of the γ camera as described above for the lungs.
Organ analysis:
At the end of the retention measurements dogs were anesthetized and sacrificed by exsanguinations. All major organs and samples of skin, muscles, lymph nodes, and bones were taken. The tracheobronchial lymph nodes (TBLN), the trachea, and the upper 3-4 generations of bronchi were separated from the rest of the lungs. Background radiation was measured and detector sensitivity was determined using aqueous radiolabeled Co sources.
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Retention:
Lung burden dropped rapidly by 89 % during the first few days with a biological half-life time (BHLT) of 0.8 days, another 8 % were eliminated with a BHLT of 27 days, and the remaining 3% of the initial burden were retained in the lungs with a BHLT of 400 days. - Details on distribution in tissues:
- Tissue distribution:
After inhalation of the aerosol, most of the radioactive Co was found in the lungs, followed by muscle, bone and skin. The amounts of Co in muscle, bone and skin were estimated, assuming 40 % of the dog's body mass for muscle and 10 % each for bone and skin (according to: Anderson AC (1970). The Beagle as an Experimental dog. Ames, IA: Iowa University Press). The organs involved in the digestive process retained small amounts of Co in the range of 1 %. No significant amount of Co was found in the exsanguinations blood sample at the time of death (less than 0.01 % due to detection limit). Negligible amounts of Co were observed in the various lymph nodes outside the lungs or in thymus, thyroids and tonsils. Brain, heart and pancreas retained small amounts, which together constituted only about 1 % of the total body burden.
Cobalt distribution inside the lungs:
The dogs showed considerably increased Co concentrations in the pharynx, trachea and first 3 -4 generations of bronchi at times corresponding to predominant long-term retention. Moreover, concentrations in these fractions increased with extending time before sacrifice.
- Details on excretion:
- Clearance pathways:
Comparison of lung retention with daily faecal and urinary excretion showed that by a few days after exposure, urinary excretion was the predominant pathway from the body. The fecal excretion rate was about one order of magnitude less and its curve proceeded parallel to the former. No significant activity was observed outside the lungs, indicating that almost all the Co cleared from the lungs was excreted and there was little storage in other organs. The clearance rate of Co from the lungs was very similar to the sum of the faecal and urinary excretion rates. The concentration in blood proceeded parallel to the urinary excretion rate, as long as it was determined, usually 150-200 days after exposure.
Excretion of cobalt after ingestion of cobalt nitrate:
About 95 % of the administered Co was excreted during the first week, about 25 % were absorbed and excreted via urine, 70 % were excreted in faeces. The remaining 5 % were retained and well distributed in the body, there was no significant accumulation in any organ at that time point.
Excretion of cobalt after i.v. and i.m. injection of cobalt nitrate:
Masses of 1 ng and 1 mg of Co administered i.v. did not show a mass dependent clearance effect. 90 % of the administered mass were excreted within the first week, 85 % via urine and 5 % in faeces. Co was homogeneously distributed within the body. The liver was the only organ accumulating sufficient amounts of Co to be distinguishable during the first week. After this time no particular organ accumulation was detectable (see table 3). The long-term retained fraction was estimated to be about 10 % by balance calculations involving excretion measurements during the next 5 weeks.
Since inhalation was carried out via an endotracheal tube, no particles were deposited outside the lungs. Therefore, 2 major clearance mechanisms were likely: particle dissolution, including subsequent translocation into the blood, and mucociliary particle transport from the lungs after inhalation. There was a small but significant transfer of Co from the circulatory system to the gastrointestinal tract and vice versa. Most of the soluble Co was excreted very rapidly.
When cobalt nitrate particles entered the humid respiratory tract they would dissolve and lose their particle structure. More than 80 % of the initial lung burden were absorbed into the circulatory system during the first day and excreted via urine. Because of the rapid exchange between the blood and the bronchial mucus and fluid, the mucociliary clearance of tracheobronchially deposited Co was assumed to be negligible.
Long-term retained Co was cleared predominantly by translocation into the blood and subsequent excretion via urine.
Metabolite characterisation studies
- Metabolites identified:
- not measured
Any other information on results incl. tables
Table 1: Tissue distribution of cobalt at the time of death obtained from one dog after inhalation:
% of total body burden | ||
Time after exposure (days) | 1050 | 1500 |
Lungs | 77 | 81 |
Bones | 10 | 8 |
Muscles | 8 | 6 |
Skin | 2 | 3 |
Stomach/Intestine | 0.8 | 0.5 |
Liver | 1 | 0.6 |
Kidneys | 0.7 | 0.5 |
Spleen | 0.1 | 0.1 |
Other organs | 0.3 | 0.3 |
Table 2: Cobalt distribution inside the lungs:
% of total lung burden | ||
Time after exposure (days) | 1050 | 1500 |
Lungs | 48 | 29 |
Pharynx, trachea, first 3-4 generations of bronchi | 52 | 71 |
Tracheobronchial lymph nodes | 0.1 | 0.1 |
Table 3: Rapid excretion during the first week and long-term retention after injection or ingestion:
Injection | Ingestion | ||
intravenous | intramuscular | ||
Co mass (µg) | 10e-3 to 10e3 | 2 x 10e3 | 2 x 10e3 |
No. of dogs | 4 | 2 | 2 |
Rapid excretion (%) during the first week after administration: | |||
Feces | 5 | 5 | 70 |
Urine | 85 | 85 | 25 |
Long-term retention (%): | |||
Liver/Spleen | - | - | - |
Soft tissues, Bones, etc. | 10 | 10 | 5 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.